Table 2.
Association of FDG-PET/CT parameters with clinicopathological parameters.
| SUVmax | MTV3.5 | TLG3.5 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| mean ± SD | R2 | P | mean ± SD | R2 | P | mean ± SD | R2 | P | |
| Sex | 0.115 | 0.161 | 0.141 | ||||||
| Male | 4.75 ± 1.60 | 3.11 ± 4.68 | 13.71 ± 20.98 | ||||||
| Female | 5.49 ± 2.06 | 4.98 ± 6.50 | 22.03 ± 26.00 | ||||||
| Age | 0.03 | 0.135 | <0.001 | 0.808 | <0.001 | 0.985 | |||
| Pre-treatment CA19-9 | 0.011 | 0.380 | 0.039 | 0.093 | 0.048 | 0.063 | |||
| Resectability | 0.0379* | 0.0125* | 0.0096† | ||||||
| R | 4.74 ± 1.59 | 2.68 ± 3.67 | 11.84 ± 16.53 | ||||||
| BR | 5.66 ± 2.04 | 6.02 ± 7.51 | 26.53 ± 30.74 | ||||||
| Tumor size | 0.051 | 0.053 | 0.2562 | <0.0001§ | 0.273 | <0.0001§ | |||
| Differentiation | 0.333 | 0.7130 | 0.6944 | ||||||
| Well | 4.43 ± 1.54 | 4.29 ± 4.97 | 16.45 ± 29.40 | ||||||
| Mod | 5.24 ± 1.83 | 4.01 ± 4.97 | 18.25 ± 22.81 | ||||||
| Poor | 4.83 ± 1.97 | 1.88 ± 2.25 | 8.62 ± 11.75 | ||||||
| pT | 0.077 | 0.1820 | 0.1102 | ||||||
| 2 | 4.07 ± 1.99 | 2.15 ± 3.03 | 9.06 ± 12.81 | ||||||
| 3 | 4.72 ± 1.70 | 2.91 ± 5.28 | 12.51 ± 20.94 | ||||||
| 4 | 5.64 ± 1.80 | 5.30 ± 5.60 | 24.03 ± 25.53 | ||||||
| LN metastasis | 0.0437* | 0.6441 | 0.4716 | ||||||
| Yes | 5.61 ± 1.89 | 3.55 ± 6.00 | 15.21 ± 24.46 | ||||||
| No | 4.73 ± 1.67 | 4.17 ± 4.31 | 19.31 ± 20.50 | ||||||
Data are expressed as mean ± SD (range) or number of patients.
*P < 0.05; †P < 0.01; §P < 0.001.
BR, borderline resectable; CA19-9, cancer antigen 19-9; LN, lymph node; MTV, mean tumor volume; R, resectable; SD, standard deviation; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.